Corporate Information
Profile
| Name | STELLA PHARMA CORPORATION |
|---|---|
| Established | June 1, 2007 |
| Headquarter | 3-2-7 Korai-bashi, Chuo-ku, Osaka, Osaka Prefecture 541-0043 |
| Description of business | Research, development, manufacturing, and sales of pharmaceuticals |
| Capital | 1.9 billion yen |
| Shareholders | Stella Chemifa, Innovation Network Corporation of Japan, Sumitomo Heavy Industries, Ltd. |
| Chairman & CEO | Tomoyuki Asano |
| President & COO | Koki Uehara |
| Number of employees | 47 (as of June 2020) |
| Laboratory | Sakai R&D Center |
| Branch | Tokyo |
History
| June 2007 | Stella Pharma founded |
|---|---|
| July 2008 | First-class marketing license for pharmaceuticals obtained (Osaka Prefecture) |
| December 2013 | First-class marketing license for medical devices obtained (Osaka Prefecture) |
| January 2014 | The Sanpo and Nakamozu laboratories merged with the Sakai R&D Center |
| March 2020 | Received marketing and manufacturing approval in Japan for STEBORONINE® 9000mg/300mL for infusion for the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer |
| May 2020 | Launched STEBORONINE® 9000mg/300mL for infusion in Japan |
